Danny Tobey is a lawyer, medical doctor and software entrepreneur who represents life
sciences, technology and healthcare clients in a variety of regulatory and litigation matters
involving FDA, CDC, HHS, CMS, private payers, and tort and commercial litigants. Danny leads
Insider’s 2022 list of top lawyers helping companies adopt artificial intelligence (AI) and leads
DLA Piper’s team helping companies navigate the legal landscape of emerging and disruptive
technologies including AI and data science. The Library of Congress gave Danny a Burton
Award recognizing “the best of the best writers in the legal profession” among the nation’s top
1,000 largest law firms.

Danny is a thought leader on legal issues in medicine and AI. He sits on Pfizer’s Digital Health
Scientific Advisory Board and on the Executive Committee of the UN’s AI for Good legal track.
In 2022, he moderated the closed-door Ministerial Roundtable in Morocco on Improving Health
Outcomes in Africa through Innovative Solutions. Danny advised the American Medical
Association on its AI and medical liability policy and was an invited speaker at the inaugural AI,
Ethics, and Society conference sponsored by Google and IBM. He guides leading global
pharmaceutical, robotics, and device companies on adopting and designing AI systems and has
helped create and implement enterprise-wide AI governance policies. His clients include IDx,
the first FDA-approved fully autonomous AI diagnostic, with whom he authored the peer-reviewed Lessons Learned About Autonomous AI: Finding a Safe, Efficacious, and Ethical
Path Through the Development Process.

A graduate of Harvard College, Yale Law School, and UT Southwestern Medical School, Danny
has handled successfully some of his clients’ most challenging and important matters. He
played a key legal role in the Covid vaccine effort, designed the winning scientific case in the
first Hatch-Waxman suit in the Eastern District of Texas, and obtained a unanimous reversal in
federal appellate court in an R&D tax case of first impression. He has successfully handled as
lead counsel litigations arising from biotech M&A transactions and has resolved board and
shareholder disputes for life-science companies. Danny has represented healthcare clients in
matters ranging from credentialing and internal investigations to peer review and business tort
claims. In addition to his legal career, Danny led a successful software company from inception
to acquisition.